Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089356 | 1.00 | CASP3 (0.56) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL8483923 | 0.89 | CASP3 (0.47) | CASP3KMT2APTPN1EPHX2 | |
| SCHEMBL377860 | 0.86 | CASP3 (0.60) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL1509157 | 0.85 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL25186508 | 0.85 | CASP3 (0.59) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL29400907 | 0.85 | CASP3 (0.59) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL119197 | 0.85 | CASP3 (0.59) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL14265318 | 0.85 | CASP3 (0.59) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL30759963 | 0.85 | CASP3 (0.59) | CASP3KMT2APTPN1MDM4TP53 | |
| SCHEMBL119762 | 0.85 | CASP3 (0.61) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039915-A1 | IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2016-02-11 | — | — | US | disclosed |
| US-8809498-B2 | Pepstatin A derivatives | FREIE UNIVERSITAET BERLIN (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8809498-B2 | Pepstatin A derivatives | FREIE UNIVERSITAET BERLIN (DE) | 2014-08-19 | — | — | US | disclosed |
| US-20140086937-A1 | IMMUNOLOGICAL CONTROL OF BETA-AMYLOID LEVELS IN VIVO | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2283030-B1 | PEPSTATIN A DERIVATIVES | UNIV BERLIN FREIE (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410028-B2 | Methods for synthesis of encoded libraries | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120252730-A1 | PLATELET AGGREGATION INHIBITORS | UNIVERSITY OF CHICAGO (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252730-A1 | PLATELET AGGREGATION INHIBITORS | UNIVERSITY OF CHICAGO (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2007053358-A2 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060228371-A1 | Immunological control of beta-amyloid levels in vivo | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2006-10-12 | — | — | US | disclosed |
| US-20050147613-A1 | Immunological control of beta-amyloid levels in vivo | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2005-07-07 | — | — | US | disclosed |
| US-6872554-B2 | Immunological control of β-amyloid levels in vivo | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030235897-A1 | Immunological control of beta-amyloid levels in vivo | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2003-12-25 | — | — | US | disclosed |
| US-6582945-B1 | Vectorized antibody for use in the treatment of alzheimer's disease | BOSTON BIOMEDICAL RESEARCH INSTITUTE | 2003-06-24 | — | — | US | disclosed |
| US-20020136718-A1 | Immunological control of beta-amyloid levels in vivo | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2002-09-26 | — | — | US | disclosed |
| US-20020102261-A1 | Immunological control of beta-amyloid levels in vivo | BOSTON BIOMEDICAL RESEARCH INSTITUTE (US) | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245040-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | CASP3 4851/4885KMT2A 1848/4885PTPN1 4052/4885 |
| US-20120252730-A1 | PLATELET AGGREGATION INHIBITORS | PTAFR, PFKP, TNNI3 | CASP3 1234/4885KMT2A 4834/4885PTPN1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.